Papillary intralymphatic angioendothelioma
puh-PIL-uh-ree in-truh-LIM-fuh-tik an-jee-oh-en-doh-THEE-lee-oh-mah
Also known as: Dabska tumor, Endovascular papillary angioendothelioma
At a Glance
What is Papillary intralymphatic angioendothelioma?
Papillary intralymphatic angioendothelioma is a rare vascular tumor that primarily affects the skin and soft tissues. It is caused by abnormal growth of endothelial cells within the lymphatic vessels. Over time, the tumor can grow slowly and may spread to nearby tissues, but it rarely metastasizes to distant organs. Early symptoms might include a small, painless lump or swelling, while later symptoms can involve pain or discomfort as the tumor enlarges. Early diagnosis is crucial to prevent complications and to start appropriate treatment. This condition can be challenging for families due to the uncertainty and potential need for multiple medical consultations. The prognosis is generally favorable with treatment, although recurrence can occur. Daily life for affected individuals may involve regular medical check-ups and monitoring for any changes in the tumor. Surgical removal is often the treatment of choice, and in some cases, additional therapies may be needed. The condition does not usually affect life expectancy but can impact quality of life. Support from healthcare professionals and patient support groups can be beneficial for managing the condition. Affected individuals may need to adapt to changes in physical appearance or function depending on the tumor's location.
Medical Definition
Papillary intralymphatic angioendothelioma is a rare vascular neoplasm characterized by papillary structures lined by endothelial cells within lymphatic vessels. Histologically, it shows intralymphatic papillary projections with a hobnail appearance of endothelial cells. It is classified as a low-grade angiosarcoma due to its potential for local recurrence and rare metastasis. Epidemiologically, it is extremely rare, with cases reported primarily in children and young adults. The disease course is typically indolent, with slow growth and a low risk of distant metastasis. Treatment usually involves surgical excision, with a focus on achieving clear margins to prevent recurrence.
Papillary intralymphatic angioendothelioma Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Localized swelling manifests as a noticeable enlargement of the affected area, often accompanied by a palpable mass. This occurs due to the proliferation of endothelial cells within lymphatic vessels, leading to obstruction and fluid accumulation. Over time, the swelling may increase in size and become more pronounced, potentially causing discomfort. It can significantly impact daily activities by restricting movement or causing pain, and management may include surgical intervention or compression therapy.
Pain is often experienced as a dull ache or sharp sensation in the affected region. It results from the pressure exerted by the growing tumor on surrounding tissues and nerves. As the condition progresses, the intensity of pain may increase, becoming more persistent and debilitating. Pain can interfere with daily activities and sleep, and management typically involves analgesics or other pain-relief strategies.
Skin discoloration appears as a bluish or reddish tint over the affected area. This occurs due to the vascular nature of the tumor, which causes increased blood flow and changes in skin pigmentation. Over time, the discoloration may become more pronounced and widespread. It can affect the patient's self-esteem and may be managed with cosmetic treatments or camouflage techniques.
Common
Fatigue presents as a persistent feeling of tiredness and lack of energy. It is often a result of the body's response to chronic inflammation and the metabolic demands of the tumor. As the disease progresses, fatigue may worsen, impacting the patient's ability to perform daily tasks. Management includes rest, nutritional support, and addressing underlying causes such as anemia.
Weight loss occurs as an unintended reduction in body weight. It can be caused by increased metabolic demands of the tumor and decreased appetite due to pain or discomfort. Over time, significant weight loss can lead to malnutrition and muscle wasting. Nutritional support and appetite stimulants may be necessary to manage this symptom.
Lymphadenopathy is characterized by the enlargement of lymph nodes near the affected area. This occurs due to the spread of the tumor or reactive changes in the lymphatic system. Over time, the lymph nodes may become more prominent and tender. It can cause discomfort and may require biopsy or imaging studies for evaluation.
Less Common
Fever is experienced as an elevated body temperature, often accompanied by chills and sweating. It may result from the body's immune response to the tumor or secondary infections. As the condition progresses, fever episodes may become more frequent and severe. Antipyretics and addressing the underlying cause can help manage this symptom.
Night sweats are episodes of excessive sweating during sleep, leading to damp clothing and bedding. They may be caused by the body's response to the tumor or hormonal changes. Over time, night sweats can disrupt sleep and lead to fatigue. Management includes maintaining a cool sleeping environment and addressing any underlying conditions.
What Causes Papillary intralymphatic angioendothelioma?
Papillary intralymphatic angioendothelioma, also known as Dabska tumor, is associated with genetic alterations involving the YAP1 gene located on chromosome 11q22. The YAP1 gene encodes the Yes-associated protein 1, which is a key regulator of the Hippo signaling pathway that controls organ size by regulating cell proliferation and apoptosis. Mutations or fusions involving YAP1, such as the YAP1::MAML2 fusion, can lead to the constitutive activation of the protein, disrupting normal cell cycle control. This aberrant activation results in uncontrolled cell proliferation and survival, contributing to tumorigenesis. The immediate molecular consequence is the dysregulation of downstream target genes involved in cell growth and survival, leading to excessive endothelial cell proliferation. This cellular overgrowth can cause dysfunction in the lymphatic system, as the proliferating endothelial cells form papillary structures within lymphatic vessels. Neighboring tissues may be affected by the mechanical pressure exerted by the expanding tumor mass, leading to local tissue damage and inflammation. The immune system may respond to this abnormal growth with a localized inflammatory response, which can further exacerbate tissue damage. In some cases, neuroinflammation may occur if the tumor is located near neural structures, potentially affecting nerve function. White matter degeneration is not typically associated with this condition, but local structural changes can occur due to tumor growth. Symptoms appear in a specific pattern based on the tumor's location, such as swelling or pain in the affected area. Disease severity varies between patients due to differences in genetic mutations, tumor size, and location, as well as individual immune responses.
How is Papillary intralymphatic angioendothelioma Diagnosed?
Typical age of diagnosis: Papillary intralymphatic angioendothelioma is typically diagnosed in children and young adults, often following the presentation of a slowly growing mass or lesion. Diagnosis usually occurs after patients present with symptoms such as localized swelling or pain, prompting further investigation. The condition is rare, which can lead to delays in diagnosis as it may initially be mistaken for more common vascular or lymphatic anomalies. Early diagnosis is crucial for effective management and to prevent potential complications.
Clinicians look for signs of a localized mass, often in the skin or subcutaneous tissues, which may be associated with pain or swelling. A detailed patient history is important, focusing on the duration of symptoms and any previous similar occurrences. Physical examination typically reveals a firm, non-tender mass that may have overlying skin changes. This step helps to differentiate from other soft tissue tumors and guides the need for further diagnostic testing.
Magnetic Resonance Imaging (MRI) is commonly used to assess the extent and characteristics of the lesion. Imaging may show a well-defined mass with specific signal characteristics that suggest a vascular origin. These findings help confirm the diagnosis by correlating with clinical suspicion and excluding other conditions like hemangiomas or lymphangiomas. Differential diagnoses such as malignant vascular tumors are also considered and ruled out based on imaging features.
Blood tests are generally not diagnostic but may include markers of inflammation or infection if secondary processes are suspected. Specific biomarkers for papillary intralymphatic angioendothelioma are not established, but tests may help rule out other conditions. Abnormal results might include elevated inflammatory markers if there is associated tissue reaction. Laboratory findings guide the clinician towards further imaging or biopsy for definitive diagnosis.
Genetic testing may involve sequencing of genes such as YAP1 and MAML2, which have been implicated in some cases. Mutations or gene fusions involving these genes can be identified, providing a molecular confirmation of the diagnosis. Results from genetic testing can confirm the diagnosis and are crucial for differentiating from other vascular tumors. Genetic findings also inform family counseling regarding potential hereditary aspects and recurrence risks.
Papillary intralymphatic angioendothelioma Treatment Options
Angiogenesis inhibitors are a class of drugs that target the formation of new blood vessels, which is a key feature of this tumor. These drugs work by inhibiting pathways that promote vascular growth, such as the VEGF pathway. Specific drugs used may include bevacizumab or sunitinib, which have shown efficacy in reducing tumor size in some cases. Clinical evidence for efficacy is limited due to the rarity of the condition, but case reports suggest potential benefits. Limitations include side effects such as hypertension and fatigue, and not all patients may respond to treatment.
Lymphatic drainage therapy involves manual techniques to reduce swelling and improve lymphatic circulation. The therapeutic goal is to alleviate symptoms such as swelling and discomfort associated with the tumor. Sessions are typically conducted 1-2 times per week, with each session lasting about 30-45 minutes. Measurable outcomes include reduced limb circumference and improved mobility. Long-term benefits may include enhanced quality of life and reduced risk of complications from chronic swelling.
Surgical excision is indicated when the tumor causes significant symptoms or functional impairment. The procedure involves complete removal of the tumor with clear margins to prevent recurrence. Expected benefits include symptom relief and reduced risk of local complications. Surgical risks include infection, bleeding, and potential damage to surrounding structures. Post-operative care requires monitoring for recurrence and managing any surgical site complications.
The care team typically includes oncologists, dermatologists, surgeons, and physical therapists. Specific interventions focus on symptom management, psychosocial support, and coordination of care. Psychosocial support strategies involve counseling and support groups to help patients and families cope with the diagnosis. Family education is provided to ensure understanding of the condition and its management. Long-term monitoring plans include regular follow-ups to assess for recurrence and manage any ongoing symptoms.
When to See a Doctor for Papillary intralymphatic angioendothelioma
- Sudden, severe pain in the affected area — this could indicate a rapid progression or complication requiring immediate medical attention.
- Difficulty breathing — may suggest a spread or severe impact on respiratory function, necessitating emergency care.
- Severe bleeding or bruising — could indicate a vascular complication or rupture, which is a medical emergency.
- Persistent swelling or growth in a limb — could indicate tumor progression and should be evaluated by a healthcare professional.
- Unexplained weight loss — may suggest systemic involvement and warrants further investigation.
- Chronic fatigue or weakness — could be a sign of underlying complications and should prompt a medical consultation.
- Mild discomfort or tenderness in the affected area — monitor for changes in size or pain, and consult a doctor if it worsens.
- Occasional mild swelling — keep track of frequency and duration, and seek medical advice if it becomes persistent.
Papillary intralymphatic angioendothelioma — Frequently Asked Questions
Is this condition hereditary?
Papillary intralymphatic angioendothelioma is not typically considered hereditary. The probability of passing it to children is low, as it often occurs sporadically. De novo mutations may occur, but they are not well-documented in this condition. Carrier status is not applicable due to its non-hereditary nature. Genetic counseling is recommended for affected individuals to understand their specific case.
What is the life expectancy for someone with this condition?
Life expectancy can vary significantly based on the age of onset and the location of the tumor. Prognosis is generally better when diagnosed early and treated promptly. Mortality is often related to complications such as metastasis or organ dysfunction. Effective treatment can improve survival rates, but outcomes depend on individual circumstances. Patients should have realistic expectations and discuss prognosis with their healthcare provider.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves imaging studies followed by a biopsy to confirm the presence of papillary intralymphatic angioendothelioma. The time from first symptoms to diagnosis can vary, often taking several months due to the rarity of the condition. Specialists such as dermatologists, oncologists, and pathologists are commonly involved. Delayed diagnosis may occur due to the condition's rarity and nonspecific symptoms. A definitive diagnosis is confirmed through histopathological examination.
Are there any new treatments or clinical trials available?
Current research is exploring targeted therapies and novel approaches such as gene therapy. ClinicalTrials.gov is a valuable resource for finding ongoing trials related to this condition. Patients should discuss potential trial participation with their doctor to understand eligibility and benefits. New treatments are in development, but timelines for availability can vary. Staying informed about research advancements is crucial for accessing emerging therapies.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care, especially if it affects limbs or vital organs. Educational and occupational adjustments may be necessary due to physical limitations or treatment schedules. Social and emotional challenges include coping with a rare diagnosis and potential isolation. Family members may experience increased caregiving responsibilities and emotional stress. Supportive resources and adaptations, such as physical therapy and counseling, can significantly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Papillary intralymphatic angioendothelioma: Dabska tumor.
Silva TS, Araujo LR, Paiva GR et al. · An Bras Dermatol · 2020 · PMID: 32151408
- 2.A huge spleen with papillary intralymphatic angioendothelioma.
Li T, Yu J, Sun X et al. · Dig Liver Dis · 2024 · PMID: 37989615
- 3.Endovascular Papillary Angioendothelioma.
Bhatia J, Tadi P · Unknown Journal · 2026 · PMID: 32965816
- 4.Papillary intralymphatic angioendothelioma with a novel YAP1::MAML2 fusion.
Shen L, Xue X, Jiang T et al. · Pathology · 2025 · PMID: 40738788
- 5.Papillary intralymphatic angioendothelioma: An extremely rare tumor.
Kaplan GO, Menku Özdemir FD, Orhan D et al. · Jt Dis Relat Surg · 2021 · PMID: 33463445
- 6.Papillary intralymphatic angioendothelioma of the thigh: A case report and review of the literature.
Ward KA, Ecker PM, White RR et al. · Dermatol Online J · 2010 · PMID: 20409411
- 7.Papillary Intralymphatic Angioendothelioma Versus Splenic Lymphatic Malformation With Papillary Endothelial Proliferation: Different Terms for the Same Entity.
Debelenko L, Remotti F · Am J Surg Pathol · 2024 · PMID: 38497350
- 8.Primary intraosseous papillary intralymphatic angioendothelioma of the distal femoral epiphysis: a case report with literature review.
Pozo-Kreilinger JJ, Pena-Burgos EM, Ortiz-Cruz EJ et al. · Skeletal Radiol · 2025 · PMID: 38619614
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-22